Evidence map›Paper›PMID 26322824›Full record

ArticleNature chemical biology2015

Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase.

Catarina Coelho, Alessandro Foti, Tobias Hartmann, Teresa Santos-Silva, Silke Leimkühler, Maria João Romão

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 92 citations in OpenAlex.

  1. One Hundred Years of Sulfido Ligand in the Molybdenum Cofactor: New Perspectives.Chembiochem : a European journal of chemical biology · 2026
    Review
  2. Structure of human aldehyde oxidase under tris(2-carboxyethyl)phosphine reducing conditions.Acta crystallographica. Section F, Structural biology communications · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. The pyridazine heterocycle in molecular recognition and drug discovery.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Enzyme Kinetics, Pharmacokinetics, and Inhibition of Aldehyde Oxidase.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Catarina CoelhoResearch Unit on Applied Molecular Biosciences-Rede de Química e Tecnologia (UCIBIO-REQUIMTE), Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.
Alessandro FotiDepartment of Molecular Enzymology, Institute of Biochemistry and Biology, University of Potsdam, Potsdam, Germany.
Tobias HartmannDepartment of Molecular Enzymology, Institute of Biochemistry and Biology, University of Potsdam, Potsdam, Germany.
Teresa Santos-SilvaResearch Unit on Applied Molecular Biosciences-Rede de Química e Tecnologia (UCIBIO-REQUIMTE), Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.
Silke LeimkühlerDepartment of Molecular Enzymology, Institute of Biochemistry and Biology, University of Potsdam, Potsdam, Germany.
Maria João RomãoResearch Unit on Applied Molecular Biosciences-Rede de Química e Tecnologia (UCIBIO-REQUIMTE), Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.
University of Potsdam · DERede de Química e Tecnologia · PTUniversidade Nova de Lisboa · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aldehyde oxidase (AOX) is a xanthine oxidase (XO)-related enzyme with emerging importance due to its role in the metabolism of drugs and xenobiotics. We report the first crystal structures of human AOX1, substrate free (2.6-Å resolution) and in complex with the substrate phthalazine and the inhibitor thioridazine (2.7-Å resolution). Analysis of the protein active site combined with steady-state kinetic studies highlight the unique features, including binding and substrate orientation at the active site, that characterize human AOX1 as an important drug-metabolizing enzyme. Structural analysis of the complex with the noncompetitive inhibitor thioridazine revealed a new, unexpected and fully occupied inhibitor-binding site that is structurally conserved among mammalian AOXs and XO. The new structural insights into the catalytic and inhibition mechanisms of human AOX that we now report will be of great value for the rational analysis of clinical drug interactions involving inhibition of AOX1 and for the prediction and design of AOX-stable putative drugs.

Indexed as

Aldehyde OxidaseAldehyde OxidoreductasesAnimalsCatalytic DomainCrystallography, X-RayEnzyme InhibitorsEscherichia coliHumansMiceModels, MolecularProtein BindingProtein ConformationSpecies SpecificitySubstrate SpecificityXenobioticsAldehyde OxidaseAldehyde OxidoreductasesAOX1 protein, humanAox3 protein, mouseEnzyme InhibitorsXenobiotics

Identifiers

PMID26322824
OpenAlexW2233464627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.